Oncternal Therapeutics, Inc. ONCT Income Statement

Oncternal therapeutics, inc. (ONCT)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11	Sep'10	Jun'10
Grant revenue
2,533	2,425	2,017	3,000	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Product sales, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Collaboration revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8,066	8,402	8,738	0	0	0
Operating expenses:
Cost of product sales
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Research and development
10,959	10,159	10,831	9,532	10,458	19,562	23,234	27,339	28,274	21,467	19,140	17,840	17,450	17,228	16,522	15,732	14,630	13,607	12,982	12,520	17,458	20,870	23,704	26,819	29,064	32,318	36,281	39,568	38,666	38,887	37,699	36,116	34,470	31,938	28,668	29,964	0	0	0
In-process research and development
-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
General and administrative
8,987	7,286	7,282	5,351	4,287	6,043	6,184	8,347	9,789	9,188	8,980	8,676	8,678	8,705	8,505	8,231	8,237	8,234	8,358	7,913	8,960	9,478	10,366	11,255	10,887	11,281	11,048	11,564	11,280	10,845	11,128	10,837	11,414	12,027	0	0	0	-	-
Total operating expenses
38,034	35,533	36,201	32,971	14,745	25,605	29,418	35,686	38,063	30,655	28,120	26,516	26,128	25,933	25,027	23,963	22,867	21,841	21,340	20,433	26,418	30,348	34,070	38,074	39,951	43,599	47,329	51,132	49,946	49,732	48,827	46,953	45,884	43,965	0	0	0	-	-
General and administrative expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Total costs and expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Loss from operations
-35,501	-33,108	-34,513	-31,498	-12,419	-23,749	-27,562	-34,159	-38,063	-30,655	-28,120	-26,516	-26,128	-25,933	-25,027	-23,963	-22,867	-21,841	-21,340	-20,433	-26,418	-30,348	-34,070	-38,074	-39,951	-43,599	-47,329	-51,132	-49,946	-49,732	-48,827	-46,953	-45,884	-35,899	-32,474	-34,586	0	0	0
Other income:
Change in fair value of warrant liability
-	1,268	1,245	1,131	0	-	0	0	-	-	-	-	-	-8,163	-10,892	-51,612	-8,596	-3,081	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest income
154	188	176	134	0	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total other income
-1,131	-1,080	-934	-955	400	467	418	409	320	216	94	80	45	46	42	38	58	57	-223	-211	-234	-259	1,414	1,416	1,435	1,488	66	-4	28	-19	80	150	104	398	336	373	0	0	0
Income from discontinued operations before income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	22,676	24,008	5,316	4,001	2,207	0	0	0	-	-
Income tax expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8,821	9,149	1,305	1,214	886	0	0	0	-	-
Net income from discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13,855	14,859	4,011	2,787	1,321	0	0	0	-	-
Net loss
-36,632	-34,188	-35,447	-32,453	-12,019	-23,282	-27,144	-33,750	-37,743	-30,439	-28,026	-26,436	-26,083	-17,724	-14,093	27,687	-14,213	-18,703	-30,015	-69,816	-32,808	-39,411	-32,656	-36,658	-38,516	-42,111	-45,036	-30,998	-28,577	-27,075	-27,042	-41,487	-41,779	-33,294	-31,187	-34,784	0	0	0
Loss from operations before income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-49,751	-48,747	-46,803	-45,780	-35,501	0	0	0	-	-
Income tax benefit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-8,821	-6,846	-1,305	-1,214	-886	0	0	0	-	-
Net loss from continuing operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-40,930	-41,901	-45,498	-44,566	-34,615	0	0	0	-	-
Basic (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-0.44	-0.49	-0.43	0.15	-0.23	2.48	-3.42	-0.17	-	-0.06	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Diluted (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-0.44	-0.49	-0.43	0.15	-0.40	-0.38	-3.42	-0.17	-	-0.06	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss from continuing operations (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.17	-0.11	-0.18	-0.19	-0.19	-0.17	-0.20	-0.04	-	-
Net income from discontinued operations (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.01	0.19	0.01	0.01	0.02	0.02	-0.01	-0.01	-	-
Net loss per share, basic and diluted
-0.31	1.01	-0.32	-3.38	-0.62	-0.23	-0.53	-0.68	-0.62	-0.43	-0.53	-0.40	-0.39	-	-	-	-	-	-	-	-	-	-	-0.15	-0.14	-	-0.14	-0.20	-0.20	-0.17	0.08	-0.17	-0.18	-0.17	-0.15	-0.21	-0.05	-0.24	-0.36
Basic (in shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	15,713	14,189	14,174	14,152	14,037	14,037	14,037	14,033	-	76,014	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Diluted (in shares)
-	-	-	-	-	-	-	-	-	-	-	-	-	15,713	14,189	14,174	14,344	14,952	15,485	14,037	14,033	-	76,014	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Weighted-average shares outstanding, basic and diluted
15	15	15	6	3	24,051	3	3	21,967	21,541	16,115	16,041	16,018	-	-	-	-	-	-	-	-	-	-	75,433	66,512	-	63,179	62,994	62,864	62,817	62,815	62,805	62,798	62,790	62,778	51,968	51,719	-	-
Basic and diluted
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	36,424	36,420,901